Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2Classical hematology 2

Conditions

Drug-Related Side Effects and Adverse Reactions 10Head and Neck Neoplasms 9Radiation Injuries 7Lung Neoplasms 7Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Ovarian Epithelial 5Sarcoma 3Prostatic Neoplasms 3Neurotoxicity Syndromes 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia 3Hodgkin Disease 3Breast Neoplasms 3Xerostomia 2Waldenstrom Macroglobulinemia 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neutropenia 2Neuroectodermal Tumors, Primitive, Peripheral 2Mucositis 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Cyclophosphamide 116fludarabine phosphate 101Busulfan 83Tacrolimus 75fludarabine 73Mycophenolic Acid 71Whole-Body Irradiation 65Peripheral Blood Stem Cell Transplantation 59Antilymphocyte Serum 58Cyclosporine 53Azacitidine 53Melphalan 50Cytarabine 47Filgrastim 43Methotrexate 41Granulocyte Colony-Stimulating Factor 34Decitabine 33Radiotherapy 28Thiotepa 27Cord Blood Stem Cell Transplantation 27thymoglobulin 26Stem Cell Transplantation 26Clofarabine 22Methylprednisolone 20Sirolimus 19Alemtuzumab 16venetoclax 15Specimen Handling 14sargramostim 13Etoposide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Myelodysplastic Syndromes × Amifostine × Clear all
NCT00003407 2023-02-02

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Rush University Medical Center

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Acute, Drug-Related Side Effects and Adverse Reactions

NCT00098683 2014-02-13

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Children's Oncology Group

Phase 2 Completed
10 enrolled
Classical hematologyMyeloid

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases

NCT00003827 2013-12-04

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡